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Abstract
AIM:
To detect the presence of milk fat globule-epidermal growth factor-factor 8 (MFG-E8) in human gingival
crevicular fluid (GCF) and to determine its potential role as a biomarker for periodontal disease activity.
MATERIALS & METHODS:
GCF was collected from a total of 230 sites from with seven subjects with gingivitis, twelve subjects with
chronic moderate periodontitis, fourteen subjects with chronic severe periodontitis, six subjects with
localized severe periodontitis as well as seven clinically healthy subjects. Subjects from the severe
periodontitis group received nonsurgical therapy and were re-evaluated after 4 weeks. GCF was re-collected
from thirty sites in five subjects at that point. Pocket reduction surgery was performed on the same subgroup
and GCF was collected again at the 4-month postoperative appointment. GCF collection was performed
using paper strips and analyzed for the presence of MFG-E8 and cytokines using multiplexing magnetic bead
immunoassays (Luminex xMAP with MagPlex beads). Each sample was tested using an MFG- E8 kit, a
human cytokine/chemokine kit and a human bone panel kit.
RESULTS:
MFG-E8 was detected at higher levels in sites with gingivitis and gingival health as compared to all
periodontitis groups, suggesting that MFG-E8 production is down regulated in periodontitis. Consistent with
this notion, MFG-E8 was found to significantly increase following non-surgical therapy of subjects with severe
periodontitis. Furthermore, the levels of MFG-E8 significantly increased after surgical treatment correlating
with decreased probing pocket depths. IL-1α, IL-1β, RANKL, OPG, IL-6 and IL-17A were detected at levels
consistent with those found in earlier studies. In the periodontitis treatment subgroup, the levels of RANKL,
IL-6 and IL-17A decreased with decreasing probing pocket depths.
CONCLUSIONS:
MFG-E8 was detected in human GCF collected from healthy, gingivitis and periodontitis subjects using a
magnetic bead-based immunoassay. The levels of MFG-E8 were negatively related to the level of gingival
inflammation and increased after both non-surgical and surgical treatment of periodontal disease. These data
suggest the potential of MFG-E8 as a novel biomarker of periodontal disease.
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ABSTRACT 
AIM: 
 To detect the presence of milk fat globule-epidermal growth factor-factor 8 (MFG-E8) in 
human gingival crevicular fluid (GCF) and to determine its potential role as a biomarker for 
periodontal disease activity. 
MATERIALS & METHODS: 
 GCF was collected from a total of 230 sites from with seven subjects with gingivitis, 
twelve subjects with chronic moderate periodontitis, fourteen subjects with chronic severe 
periodontitis, six subjects with localized severe periodontitis as well as seven clinically healthy 
subjects. Subjects from the severe periodontitis group received nonsurgical therapy and were re-
evaluated after 4 weeks. GCF was re-collected from thirty sites in five subjects at that point. 
Pocket reduction surgery was performed on the same subgroup and GCF was collected again at 
the 4-month postoperative appointment. GCF collection was performed using paper strips and 
analyzed for the presence of MFG-E8 and cytokines using multiplexing magnetic bead 
immunoassays (Luminex xMAP with MagPlex beads). Each sample was tested using an MFG-
E8 kit, a human cytokine/chemokine kit and a human bone panel kit. 
RESULTS: 
 MFG-E8 was detected at higher levels in sites with gingivitis and gingival health as 
compared to all periodontitis groups, suggesting that MFG-E8 production is down regulated in 
periodontitis. Consistent with this notion, MFG-E8 was found to significantly increase following 
non-surgical therapy of subjects with severe periodontitis. Furthermore, the levels of MFG-E8 
significantly increased after surgical treatment correlating with decreased probing pocket depths. 
IL-1α, IL-1β, RANKL, OPG, IL-6 and IL-17A were detected at levels consistent with those 
found in earlier studies. In the periodontitis treatment subgroup, the levels of RANKL, IL-6 and 
IL-17A decreased with decreasing probing pocket depths. 
CONCLUSIONS: 
MFG-E8 was detected in human GCF collected from healthy, gingivitis and periodontitis 
subjects using a magnetic bead-based immunoassay. The levels of MFG-E8 were negatively 
related to the level of gingival inflammation and increased after both non-surgical and surgical 
treatment of periodontal disease. These data suggest the potential of MFG-E8 as a novel 
biomarker of periodontal disease. 
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Milk Fat Globule-Epidermal Growth Factor-Factor 8 (MFG-E8) as a Novel 
Biomarker for Periodontal Disease 
 
INTRODUCTION 
 
Periodontal Disease 
Dental plaque accumulation can lead to inflammation in the gingival tissues leading to 
gingivitis. In some susceptible individuals, gingival inflammation may progress and involve the 
alveolar bone and other tooth supporting structures leading to periodontitis [1]. 
Gingivitis is characterized by inflammation which is limited to the gingival tissues 
without affecting the attachment levels of the teeth. The main etiology for this gingival 
inflammation is the microbial biofilm that accumulates on the dental structures especially with 
the lack of proper oral hygiene practices [2]. This was proven by the classic 1965 study by Loë 
[2] where subjects with good biofilm control developed gingivitis 10-21 days after abstaining 
from oral hygiene practices. Resolution of gingival inflammation was noted in the same subjects 
within one week of resuming oral hygiene practices which shows a direct relationship between 
microbial biofilm and gingivitis. 
Periodontitis compromises the integrity of the periodontium, i.e., the tooth-supporting 
structures such as the gingiva, periodontal ligament, and the alveolar bone. The disease is 
initiated by inflammation caused by dysbiotic bacterial communities forming on subgingival 
tooth sites [3]. It is broadly classified as being either chronic or aggressive [4]. Aggressive 
periodontitis differs from chronic periodontitis in the rapid rate of bone and attachment loss is 
subjects who are generally healthy, as well as having a tendency for familial aggregation [5].  
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Historically, it was accepted that periodontitis occurs as a continuation of gingival 
inflammation [6, 7]. In 1986, Loë published the results of a 15-year cohort study of Sri Lankan 
tea workers. The cohort consisted of a group of male tea workers aged between 14 and 30 years 
with no access to dental care. At the 15-year follow up, it was found that around 8% of the 
subjects had “rapidly progressing disease”, or what would be described today as aggressive 
periodontitis; 81% of the subjects were described as having “moderately progressing disease” 
while around 11% had no progression of periodontal disease [8]. This led to the conclusion that 
only a subset of the population are susceptible to periodontal disease progression and that 
periodontitis does not necessarily occur as a continuation of gingivitis. 
Many studies have been done to allow further understanding of the host’s immune 
response and its role in detecting individuals who are susceptible to periodontal disease 
progression. Overall, periodontal disease susceptibility is determined by genetic factors that 
predispose to hyperinflammatory responses or by environmental factors (e.g., diet and stress) and 
risk-related behavior (e.g., smoking) that can modify the host immune response in a destructive 
direction. Further understanding of the role of the host’s immune response to periodontal 
pathogens may allow development of new host modulatory therapies that aim to treat periodontal 
disease by targeting specific aspects of the host immune system. These therapies differ from the 
current periodontal treatment modalities which focus on treating the local, mostly microbial 
etiological factors [9]. 
Recent microbiome analyses of human dental plaque and animal model-based 
mechanistic studies collectively suggest that the pathogenesis of periodontitis is not caused by 
individual bacteria often referred to as “periopathogens” but rather involves polymicrobial 
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synergy and dysbiosis, that is, an elevation of certain populations in the oral bacterial community 
that synergistically lead to destructive inflammatory responses and bone loss [10].  
Cytokines are key mediators of the host response and play a major role in the 
pathogenesis of periodontal disease [11]. Cytokines are proteins that are involved in immune 
regulation and the inflammatory response. Graves in 2008 classified cytokines that are involved 
in the stimulation of inflammatory reactions as chemokines, innate immune cytokines and 
acquired immune cytokines [11].  
 Many pro- and anti-inflammatory cytokines have been studied in relation to periodontal 
disease. The initial immune response was characterized by the increase in protective anti-
inflammatory cytokines such as transforming growth factor-β (TGF-β), interleukin-4 (IL-4) and 
IL-10 [9, 12]. As periodontal disease progresses, the cytokine profile shows a shift from anti-
inflammatory to pro-inflammatory cytokines such as IL-1, IL-6, tumor necrosis factor-α (TNF-
α), prostaglandin E2 (PGE2) and other mediators such as matrix metalloproteinases (MMPs). 
The increase of pro-inflammatory mediators leads to periodontal tissue breakdown and bone loss 
leading to apical migration of the dental supporting structures and clinical attachment loss [13]. 
Periodontitis is typically diagnosed based on clinical and radiographic evaluation of the 
resulting alveolar bone destruction and clinical attachment loss by manual measuring of probing 
pocket depths (PPD), bleeding on probing (BOP), and radiographic bone levels [14]. These 
parameters give information about the history of periodontal infection in an individual but do not 
necessarily give information about the current activity or future disease progression [15]. The 
increasing knowledge about the host’s response in various stages of periodontal disease may 
allow the future development of more accurate diagnostic methods as well as the potential 
development of new therapeutics that target the host’s immune response. 
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Gingival Crevicular Fluid 
Gingival crevicular fluid (GCF) is a secreted fluid which is naturally found in gingival 
tissues. It is believed that in healthy gingival tissues, a transudate of interstitial fluid is secreted 
into the gingival sulcus [16]. As inflammation occurs in gingival tissue, an increased 
permeability of gingival microvascular structures is seen which leads to the secretion of an 
inflammatory exudate, which explains the increase GCF volume with increasing gingival 
inflammation [17-19]. 
The earliest published reports about the presence of secretions from the gingival fluid are 
found in the early 1950s studies of gingival pockets by Waerhaug [20, 21]. In 1958, the presence 
of gingival fluid was found accidentally by Brill and Krasse [22]. In their study, which was 
initially conducted to examine the gingival microflora in dogs, iodine solution was used to 
disinfect the teeth before sample collection and it was noted that the iodine rapidly disappeared 
from the gingival pockets. Also, fluorescein dye was intravenously injected as part of a study and 
within 30 seconds, they found that the dye was detected in the healthy gingiva of the animals and 
could be retrieved on filter paper strips [23]. This discovery of gingival fluid secretion led to 
further studies by Brill. In 1959, Brill and Bjorn showed the presence of gingival fluid secretions 
in humans with healthy gingival tissues [24]. Brill also showed that the fluid secretion is affected 
by chewing and brushing and that the fluid is related to vascular permeability. 
GCF has been used as a medium to detect various cells and molecules which are related 
to periodontal pathophysiology including the different biomarkers associated with the 
periodontal inflammatory process. 
Masada found that IL-1 was expressed in the majority of GCF samples they tested [25]. 
Their samples were taken from subjects with moderate to severe periodontal disease and subjects 
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with “early-onset periodontitis” or aggressive periodontitis. They also showed significant 
reduction of IL-1 levels in most sites with aggressive periodontitis after non-surgical periodontal 
therapy. In 1992 and 1993, Wilton detected IL-1β in GCF in 68.9% of sites with chronic 
periodontitis in one sample population and in 88.6% of sites with chronic periodontitis tested in 
another sample population [26, 27]. 
Hou studied the levels of IL-1β in GCF following phase I therapy. It was found that the 
GCF levels of IL-1β were reduced at the reevaluation appointment following non-surgical 
therapy[28]. 
Geivelis followed 5 subjects on periodontal maintenance for 6 months. GCF samples 
were taken initially prior to non-surgical therapy followed by samples after 3 months and 6 
months [29]. IL-6 in GCF showed positive correlation with inflammation as manifested 
clinically by increased probing depths and bleeding upon probing. It was also found that IL-6 
levels in GCF was increased in sites with progressive periodontal breakdown as compared to 
inactive sites. 
Mogi also reported the levels of IL-6 in GCF in subjects with periodontitis along with 
levels of IL- 1β, β2-microglobulin (B2-MG), interferon-γ (IFN-γ) and transforming growth 
factor-α (TGF-α) [30]. The sample groups were healthy periodontal sites as controls and sites 
with mild and severe periodontitis. It was found that the levels of IL-6 increased 3 times in cases 
of severe periodontitis as compared to healthy controls. The levels of IL-1β and B2-MG were 
also significantly increased in periodontitis. IFN-γ was increased in periodontitis but the increase 
was not statistically significant. TGF-α, on the other hand, had a statistically significant decrease 
in cases with mild and severe periodontitis cases as compared to healthy sites. 
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Gamonal evaluated GCF IL-1β, IL-8 chemokine, RANTES and IL-10 after provision of 
periodontal therapy in the previous study. The study enrolled 12 subjects with moderate-severe 
periodontitis and 6 periodontally healthy subjects as controls. GCF was collected from all 
subjects at baseline and was also collected 2 months after periodontal therapy in six subjects who 
received non-surgical periodontal treatment. IL-8, IL-1β and RANTES were detected in GCF 
from most sites in periodontitis subjects and that all tested cytokines were reduced in subjects 
who received periodontal therapy. Subjects with periodontitis also showed significantly higher 
GCF volume when compared to controls and that volume was reduced following periodontal 
therapy [31]. 
Vernal used ELISA to study receptor activator for nuclear factor κB ligand (RANKL) in 
GCF of periodontitis subjects and healthy subjects. They also examined GCF from subjects with 
progressive periodontal destruction. They found a significantly higher level of RANKL in 
subjects with periodontitis when compared to controls. Sites with active periodontal disease also 
showed significantly higher levels of RANKL than inactive sites [32]. 
In another study published in the same year, Mogi also used ELISA to investigate 
RANKL and osteoprotegerin (OPG) in GCF samples from subjects with various severities of 
periodontitis. They found that RANKL was barely expressed in the healthy controls but that its 
levels increase significantly with the increase in periodontal disease level. The levels of OPG, on 
the other hand, were increased in healthy states and decreased with periodontal disease. It was 
found that sites with severe periodontitis had only 12.7% of the OPG level of healthy controls 
[33]. 
Bostanci also examined OPG and RANKL in GCF from healthy, gingivitis, aggressive 
periodontitis and chronic periodontitis of healthy and immunosuppressed populations. They 
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found a significantly higher RANKL/OPG ratio in all periodontitis groups when compared to 
gingivitis and healthy sites [34]. They also examined the effect of non-surgical treatment on the 
levels of OPG and RANKL in GCF in a 4-month follow up period. No significant differences 
were found between RANKL, OPG and RANKL/OPG ratio at baseline, 2 months, 3 months and 
4 months after non-surgical therapy in subjects with chronic and generalized aggressive 
periodontitis. This led to the conclusion that although RANKL/OPG ratios may be of value in 
chronic periodontitis, it does not have much value in evaluating successful treatment [35].  
In 2005, Vernal examined GCF from sixteen subjects with chronic periodontitis and eight 
healthy controls. The samples were tested by ELISA for the presence of IL-17. The findings 
revealed that the levels of IL-17 was significantly higher in periodontitis subjects as compared to 
healthy controls [36]. 
 Silva followed subjects with moderate-severe chronic periodontitis until disease 
progression was detected. Two GCF samples were taken from 18 subjects representing an active 
and an inactive site. It was found that active sites had significantly higher levels of Receptor 
activator for nuclear factor κB ligand (RANKL), IL-1β and MMP-13 when compared to inactive 
sites [37]. 
In a study published in 2010, Offenbacher used an experimental gingivitis model to study 
the changes in composition of GCF during inflammation and resolution. Twenty-five subjects 
were enrolled in the study. All subjects underwent 1-week hygiene instruction phase, 3-weeks of 
experimental gingivitis induction using special acrylic stents that prevent brushing and flossing 
of two posterior sextants and then a 4-week resolution phase. GCF samples were collected at the 
beginning and end of the hygiene phase, followed by sample collection weekly for 3 weeks. The 
subjects were then instructed to use an electric toothbrush for 4 weeks with GCF samples being 
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collected at 2 weeks and at the end of the study period. It was found that during the experimental 
gingivitis phase, there was a significant increase in IL-1β and IL-1α and a decrease in several 
chemokine and MMP levels. The resolution of experimental gingivitis led to the reversal of these 
mediators [38]. This shows that inflammatory products in GCF reflect the degree of 
inflammation in the gingival tissues. 
Leppilahti studied MMP levels in GCF from healthy, gingivitis and chronic periodontitis 
subjects. Their aim was to use GCF biomarkers to identify sites showing attachment loss rather 
than showing inflammation alone. Fifty-eight samples were analyzed and showed a statistically 
significant increase in myeloperoxidase (MPO) and MMP-8 in the periodontitis group as 
compared to both gingivitis and periodontally healthy sites. Azurocidin and MMP-14 were 
significantly increased in periodontitis sites as compared to health sites and MMP-13 was 
significantly higher in periodontitis sites when compared to gingivitis sites. The significant 
difference of MPO, MMP-8 and MMP-13 between sites with gingival inflammation without 
attachment loss (gingivitis) as compared to sites with attachment loss (periodontitis) may show 
the potential of using those biomarkers in diagnosing sites with attachment loss [39]. 
Most of the published research on the use of GCF biomarkers provides data that 
differentiates periodontal disease status but does not give information about potential of 
periodontal disease progression. A recently published paper showed the results of a longitudinal 
study aiming to evaluate the use of GCF biomarkers in predicting periodontal disease 
progression. 83 subjects were divided into 4 groups, healthy, gingivitis, mild chronic 
periodontitis and moderate-severe chronic periodontitis. All subjects were monitored for 6 
months with GCF sampling done every 2 months. This was followed by a 6-month treatment 
phase in which subjects received non-surgical periodontal therapy with GCF sampling done ever 
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2 months as well. It was found that subjects in both periodontitis groups showed significant 
reduction of MMP-8, MMP-9, C-reactive protein and IL-1β in GCF during the treatment phase 
as compared to the non-treatment phase. When GCF biomarkers were compared between 
subjects that were found to be periodontally stable and those with periodontal disease 
progression it was found that the periodontally-stable subjects had a significantly lower 
biomarker level as compared to subjects with disease progression [40]. This shows the potential 
usefulness of utilizing GCF testing methods in identifying patients with susceptibility to 
periodontal disease progression which may aid in clinical decision making regarding the 
appropriate mode of therapy. 
GCF testing has been shown to reflect the inflammatory status in periodontal tissues 
during various states of health and disease. GCF collection is a simple, minimally invasive 
procedure that can be done with little or no discomfort to the patients. Advances in GCF analysis 
methods may provide new clinical tools that may allow detection of current periodontal 
inflammation status and to detect patients who maybe susceptible to periodontal breakdown. 
Additionally, advances in identification of certain biomarker profiles for different disease states 
may potentially lead researches to develop host modulatory therapies targeting specific 
biomarkers that are present in active diseased states. 
Luminex xMAP 
The immunological components of GCF and other body fluids have been typically 
analyzed using different types of immunoassays such as enzyme-linked immunosorbent assays 
(ELISAs). One disadvantage of using ELISA is the need for a separate analysis for every 
cytokine which requires a large sample volume in order to perform multiple analyses as well as 
cost and time consumption. 
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More recently, multiplexing bead-based immunoassays such as the Luminex xMAP 
technology have been introduced. These assays allow the analysis of multiple analytes 
simultaneously using small sample volumes by utilizing carboxylated polystyrene microspheres 
with fluorescent dyes. 
Elshal and McCoy reviewed the studies that compared ELISA to multiplex bead based 
assays. They concluded that ELISA and multiplex assays do show good correlation between both 
methods when variables are minimized and similar protocols are followed [41]. 
Several recent studies utilized the multiplexing bead-based immunoassays to analyze 
different biomarkers in GCF in different situations. One group of researchers collected 4 GCF 
samples 1 week post operatively from 15 subjects who underwent periodontal surgery, as well as 
4 GCF samples from uninvolved sites in the same subjects. All GCF samples were tested using a 
multiplexing bead assay for angiopoietin-1 (Ang-1), vascular endothelial growth-factor (VEGF), 
BMP-2, osteoprotegerin (OPG), tissue inhibitor of metalloprotease-1 (TIMP-1), basic fibroblast 
growth-factor (bFGF), keratinocyte growth-factor (KGF), and platelet derived growth-factor 
(PDGF).  It was found that at 1-week post periodontal surgery, GCF from surgical sites showed 
significant increase of Ang-1, VEGF, OPG and TIMP-1. This shows that multiplexing bead 
based immunoassays have the ability to provide a profile of biomarkers that characterize events 
that occur as part of periodontal wound healing [42]. 
Thunell also used multiplex fluorescent bead-based immunoassay to compare cytokine 
and chemokine levels in GCF samples before and after non-surgical periodontal therapy. 
Twenty-two cytokines and chemokine were tested but only sixteen were detected by the assay. 
The detected cytokines includes IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-6, IL-7, IFN-γ and several 
chemokines. IL-5, IL-10, IL-12, IL-13, IL-15 and TNF-a were not detected by the assay. At 
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initial assessment, levels of IL-1α and IL-1β were higher in periodontally involved sites when 
compared to periodontally healthy sites. IL-1α, IL-1β, IL-2, IL-3, IL-6, IL-7, IL-8, IL-12 among 
with CCL5, RANTES, eotaxin, macrophage chemotactic protein-1, macrophage inflammatory 
protein-1a and interferon-y were significantly reduced in periodontally involved sites after 
treatment [43]. 
Shimada used multiplex fluorescent bead assays to test GCF from patients on periodontal 
maintenance for 40 biomarkers including interleukin (IL)-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-
12, IL-13, IL-17A. The assay detected twenty-six biomarkers in all samples. Nine biomarkers, 
including MMP-3, IL-1β, IL-21, RANTES, showed significantly higher levels in healthy sites 
when compared to diseased sites [44]. 
A group of researchers published two studies that used multiplexing bead based assays to 
analyze GCF in subjects with generalized aggressive periodontitis. Their findings were that 
subjects with generalized aggressive periodontitis showed significantly higher levels of IL-1β, 
granulocyte-macrophage colony-stimulating factor (GM-CSF) and IL-1β/IL-10 ratio. Another 
finding of their study was that the different GCF cytokine profiles appear with different 
composition of biofilm bacterial complexes[45]. Six months after non-surgical therapy of the 
generalized aggressive periodontitis group, GCF samples were collected again and compared to 
baseline. It was found that there was significant reduction in GM-CSF, IL-1β and IL-1β/IL- 10 
ratio in GCF after non-surgical treatment, with and without the administration of systemic 
antibiotics. It was also noted that GCF of IL-6, which is an pro-inflammatory cytokine, was 
increased after the same treatment [46]. 
A more recent study was done on GCF samples from healthy, gingivitis and periodontitis 
subjects. Multiplexing bead based analysis was also used to detect GCF levels of interferon 
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(IFN)-γ and interleukin (IL)-4, IL-33 and thymic stromal lymphopoietin (TSLP). The significant 
finding of this study was that IFN-γ was found to be significantly less in healthy sites in the 
periodontitis group than inflamed sites in the gingivitis group. This indicates that IFN-γ can be 
used as a site-specific biomarker for inflammation regardless of the patient’s periodontal disease 
classification [47]. 
The previous studies have shown the advantage of using Luminex xMAP in detecting 
multiple mediators in a small amount of fluid with less number of assays. Multiplexing assays 
seem to have an advantage in analyzing GCF due to the typically limited volume of collected 
GCF samples especially in periodontally healthy states. 
MFG-E8 
Milk Fat Globule-Epidermal Growth Factor-Factor 8 (MFG-E8) or lactadherin is a 
secreted glycoprotein found on the milk fat globule membrane [48]. The N-terminal domains of 
MFG-E8 are similar in structure to epidermal growth factor (EGF) while the C-terminal domains 
are F5/8 type C which resemble coagulation factors V and VIII [49]. 
The name MFG-E8 came after the identification of epidermal growth factor-like regions 
as well as sequences that are similar to coagulation factors V and VII on a protein on the 
membrane of milk fat globules secreted by murine mammary epithelial cells [50]. They also 
reported the discovery of this same protein in lactating and non-lactating mice though its level 
was significantly increased during lactation. Analogous proteins with similar structures were 
later identified in bovine and guinea pig milk samples, as well [51-54]. 
In humans, Larocca group identified a protein that was termed BA46 in the milk fat 
globule membrane of subjects who were in the eighth months of pregnancy and underwent 
mastectomies due to breast tumors. Their findings have shown that the two C-terminals of BA46 
MFG-E8 and Periodontal Disease 17 
shared 43% with the sequence of coagulation factor V and 38% with coagulation factor VIII. 
They also found that the area of the C-terminal is 60% identical to the same region in the murine 
MFG-E8 protein which was described by Stubbs [55].  
In 1996, Couto group further studied BA46 and found that it contains a single epidermal 
growth factor-like domain which has an arginine-glycine-aspartic acid (RGD) tripeptide 
sequence identical to that found previously on one of the epidermal growth factor-like domains 
in murine MFG-E8. Their findings suggested that murine MFG-E8 is related to human BA46 
even though they do have some differences in structure which maybe related to different 
functional requirements of mice vs. Humans [56].  
Taylor examined the RGD sequence of BA46 in humans, they found that the RGD 
sequence plays a role in cell adhesion by binding to cellular integrin receptors which led to 
replacing the name of BA46 to lactadherin [57]. 
In 1997, Collins group reported the identification of a gene that is homologous to the 
gene of murine MFG-E8 in human infant brain DNA which they named huMFG-E8 [58]. They 
noted that this gene contains a sequence that is identical to the partial gene sequence of BA46 
which was reported by Larocca which suggests that BA46 and huMFG-E8 might be identical 
[55, 58]. 
Further investigations of MFG-E8 have shown that MFG-E8 is not exclusively related to 
lactation as was initially thought. It was found in mouse fetal gonadal tissue and that it plays a 
role in gonadogenesis [59]. It was also found that it is secreted by macrophages and plays a role 
in cell apoptosis [60-62]. The expression of MFG-E8 has also been reported in Langerhans cells, 
skin dendritic cells [61], epidermal keratinocytes [63], retina and retinal pigment epithelium [64] 
as well as brain microglial cells [65, 66], pericytes [67] and endometrial cells [68, 69]. 
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Different authors investigated the role of MFG-E8 in different conditions [70]. It was 
found to play a role in clearing apoptotic cells, as mentioned previously. This was first reported 
by Hanayama, they found that the C-terminal domains of MFG-E8 binds to apoptotic cells while 
the RGD motif on the N-terminal binds to phagocytes in preparation to phagocytosis [60, 61]. 
On the other hand, mice lacking in MFG-E8 showed reduced lymphocyte apoptosis leading to a 
pathological autoimmune reaction [71-73] as well as reduced apoptosis of atherosclerotic 
plaques in cases of atherosclerosis [74]. 
MFG-E8 was also found to play a role in Alzheimer's disease [75, 76], systemic lupus 
erythematous [77-79], repair of intestinal epithelium [80], stroke [81], asthma [82], pancreatitis 
[83], diabetic nephropathy [84], obesity [85], cardiovascular diseases [86] as well as tumor 
development [87-89], sepsis and ischemia-reperfusion injuries [90-92] and wound healing [92] 
due to increased angiogenesis [67, 93]. 
In 2014, a paper was published by Abe et al investigating the role of MFG-E8 in 
periodontitis in mice. Ligatures were used to induce periodontal inflammation and bone loss [94] 
in MFG-E8-/- mice as well as wild-type mice which were used as controls. It was found that the 
level of MFG-E8 mRNA was significantly reduced within the first 24 hours. This was followed 
by a period of elevation that occurred with the appearance of osteoclasts and multinuclear cells 
up to the eighth day. Following that, a period of reduced expression was noted (around day 10) 
following the drop in osteoclast count. Further examination of this relationship between 
osteoclast levels and MFG-E8 expression revealed that MFG-E8 is expressed by osteoclasts 
involved in periodontal bone loss. The role of MFG-E8 in osteoclastogenesis was investigated by 
comparing MFG-E8-/- mice with wild-type mice. It was found that osteoclastogenesis was more 
efficient in the absence of MFG-E8 and that the application of MFG-E8 to knock-out mice led to 
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inhibition of osteoclastogenesis. The application of MFG-E8 to human osteoclast progenitors in 
vitro also inhibited osteoclast differentiation and maturation. In vivo, MFG-E8-/- mice 
undergoing ligature-induced periodontitis as well as those with naturally occurring periodontitis 
showed increased number of osteoclasts and periodontal bone loss as compared to controls 
which led to the conclusion that MFG-E8 negatively regulates periodontal bone loss [95]. 
Recombinant MFG-E8 was injected mice with ligature-induced periodontitis and was 
found to inhibit bone loss in both wild-type and MFG-E8-/- groups which may suggest the use of 
MFG-E8 as a local therapeutic agent in treatment of periodontitis [95]. 
In summary, the above-described studies have shown that MFG-E8 is expressed in 
various tissues, including the periodontium, and mediates diverse homeostatic functions 
including suppression of inflammation, apoptotic cell removal, and regulation of 
osteoclastogenesis 
 
AIM 
The primary aim of this current research was to detect for the first time the presence of 
MFG-E8 in human GCF of subjects with gingivitis, periodontitis and periodontal health and to 
determine the role of MFG-E8 as a biomarker to detect periodontal disease activity. The 
secondary aim was to test the usefulness of the magnetic multiplexing assays in analyzing 
multiple inflammatory mediators in small GCF samples and to relate the MFG-E8 levels to those 
of cytokines previously shown to play a role in periodontitis. 
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MATERIALS & METHODS 
Participants 
A group of patients presenting to the Penn Dental Medicine Graduate Periodontal Clinic, 
The University of Pennsylvania, Philadelphia, PA were recruited to participate in this cross-
sectional study from January 2013 to June 2014. The subjects enrolled were grouped as healthy 
(H), gingivitis (G), moderate periodontitis (Pm), severe periodontitis (Ps) or localized aggressive 
periodontitis (LAP). 
The main inclusion criteria were adult subjects with good general health and with at least 
10 teeth in the functional dentition excluding third molars and who had never received 
periodontal treatment at the time of initial clinical examination. All subjects were required to be 
able to read and understand the written consent form. For patients with periodontitis, at least two 
quadrants had to involve deep probing depths (PD), clinical attachment loss (CAL) and 
detectable radiographic bone loss. 
Subjects with the following conditions were excluded: 
1. Smoking, drug or alcohol abuse. 
2. Uncontrolled diabetes. 
3. Previous head and neck radiotherapy. 
4. History of chemotherapy in the previous 12 months. 
5. Immunocompromised subjects or subjects suffering from systemic diseases that 
significantly affect the periodontium. 
6. Subjects taking medications known to affect the periodontium (e.g. Phenytoin, calcium 
channel blockers, cyclosporine…etc). 
7. Pregnant or lactating females. 
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8. Subjects requiring prophylactic antibiotics. 
9. Subjects taking steroid medications except for acute topical treatment. 
10. Subjects using systemic antibiotics within three months prior to enrollment. 
11. Subjects who currently have, or history of (within three months), of the following 
diseases: severe cardiovascular, pulmonary or liver diseases, end stage renal disease, 
active malignancy, cerebral vascular disease, HIV, TB, hepatitis or other active infectious 
diseases. 
All subjects who volunteered to participate underwent routine periodontal examination 
and were classified according to the Armitage Classification System [4] as either having plaque-
induced  gingivitis, chronic moderate periodontitis, chronic severe periodontitis, localized 
aggressive periodontitis or being periodontally healthy. 
Subjects with PD < 3 mm, no signs of gingival inflammation, CAL, bleeding on probing 
(BOP) or radiographic bone loss were placed in the healthy group. Subjects with PD < 3 mm, 
with signs of gingival inflammation or BOP but without CAL or radiographic bone loss were 
placed in the gingivitis group. The Moderate Periodontitis group included subjects with CAL of 
3-4 mm and moderate radiographic bone loss. Subjects with CAL of 5 mm or more with severe 
radiographic bone loss were placed in the severe periodontitis group. Subjects with minimal 
amount of gingival inflammation and BOP with CAL and radiographic bone loss that was 
limited to the first molars and incisors were placed in the aggressive periodontitis group. 
This study was approved by the IRB of the University of Pennsylvania (IRB #817153). 
The protocol was explained to the subjects and verbal and written consent was taken in 
accordance with the Declaration of Helsinki. 
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Sample Collection 
All samples were collected by one investigator (F. M.) after reviewing the medical 
history and performing clinical and radiographic periodontal examination and establishing a 
periodontal diagnosis. PD and CAL were measured at 6 sites for every tooth using a manual 
probe (UNC 15, Hu-Friedy, Chicago, IL, USA). Five teeth were selected from each subject with 
at least one anterior tooth and two posterior teeth from two different quadrants. The teeth were 
dried and isolated with cotton rolls and the samples were obtained from the surface with the 
deepest PD. Samples were collected using absorbent paper strips (Periopaper, ProFlow Inc., 
Amityville, NY, USA) which were placed in the selected sites until mild resistance was felt and 
kept in place for 30 seconds [96, 97]. Samples with blood or saliva contamination were 
discarded. The individual paper strips were subsequently transferred into polypropelene tubes 
(Eppendorf, Hamburg, Germany) and were frozen (-80°C) until they were ready to be analyzed. 
GCF Samples 
A total of 46 subjects were included in the analysis with a total of 230 sites. The site 
distribution was as follows: 35 sites (7 subjects) in the Healthy group, 35 sites (7 subjects) in the 
Gingivitis group, 60 sites (12 subjects) in the moderate periodontitis group, 70 sites (14 subjects) 
in the severe periodontitis group and 30 sites (6 subjects) in the aggressive periodontitis group. 
Thirty samples (5 subjects) from the severe periodontitis group were reexamined at reevaluation 
appointment after non-surgical periodontal treatment consisting of scaling and root planing and 
home care oral hygiene instructions as well as after pocket reduction surgery (Fig 1). At the time 
of analysis, the contents of the GCF samples were eluted from the paper strips using phosphate 
buffered solution. The level of MFG-E8 and other cytokines were analyzed using Luminex® 
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xMAP® multiplexing bead-based immunoassays utilizing magnetic carboxylated polystyrene 
microspheres (MagPlexTM).  
MFG-E8 
MFG-E8 was quantified with a Human Premixed Multi-Analyte Kit (R&D Systems, 
Minneapolis, MN, USA). The assay was done according to manufacturer’s instructions. The 
diluted magnetic micro particle cocktail was added to the wells of a 96-well magnetic plate. 
Samples and standards were added in duplicate to the magnetic beads and incubated for 2 hours 
at room temperature with shaking on a plate shaker. The wells were then washed three times 
with the supplied Wash Buffer using a magnetic plate holder. Diluted Biotin Antibody Cocktail 
was then added to each well and the plate was incubated at room temperature on a plate shaker 
for 1 hour. After that, the wash procedure was repeated and diluted Streptavidin-PE was added to 
each well. The plate was sealed and incubated for 1 hour on a shaker at room temperature. The 
plate was then washed and the microparticles were resuspended in Wash Buffer and incubated on 
a shaker for 2 minutes. The plate was then ready to be read by the Milliplex Analyzer (EMD 
Millipore, Darmstadt, Germany).  
Other Analytes 
All samples were also analyzed using HCYTMAG-60K-PX30 Human 
Cytokine/Chemokine Magnetic Bead Panel Kit (EMD Millipore, Darmstadt, Germany) to detect 
levels of Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, 
IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-17, TNF-α and TNF-β. The assay was performed 
according to the manufacturer’s instructions. The diluted Wash Buffer was added to the wells of 
a 96-well plate and the plate was sealed and shaken on a plate shaker for 10 minutes at room 
temperature. The plate was then decanted and dried. Standards and Controls were added in 
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duplicate to the specified wells followed by PBS. Diluted Assay Buffer was added to the sample 
wells followed by the samples which were also added in duplicate. After that, the premixed 
beads were added to each well and the plate was sealed and incubated on a plate shaker 
overnight at 4°︎ C. At the following day, the plate contents were removed using a magnetic plate 
holder to retain the magnetic beads and the plate was washed twice using the Wash Buffer. 
Detection antibodies were placed into each well and the plate was sealed and incubated with 
agitation on a plate shaker for 1 hour at room temperature. After incubation, Streptavidin-
Phycoerythrin was added to each well and the plate was incubated with agitation for 30 minutes 
at room temperature. The washing procedure was repeated twice. The beads were resuspended 
by the addition of Sheath Fluid and agitation for 5 minutes and the plate was run by the Milliplex 
Analyzer (EMD Millipore, Darmstadt, Germany).  
The samples were also processed a third time using Human Bone Magnetic Bead Panel 
(EMD Millipore, Darmstadt, Germany) to detect RANKL, OPG and OPN following the same 
procedure as the human cytokine/chemokine kit.  
Statistical Analysis 
 Data were analyzed using Graphpad Prism software. Comparison between groups was 
done using Kruskal-Wallis test with Dunn's multiple comparison test for each detected analyte. 
Correlation between MFG-E8 and PPD was done using Spearman's rank-order correlation. In the 
treatment subgroup, differences after nonsurgical treatment were checked using Wilcoxon signed 
ranks test that was repeated for each analyte. p-value of 5% was considered significant. 
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RESULTS 
The current investigations shows the results of a human GCF analysis in subjects 
classified as periodontally healthy, gingivitis, moderate and severe periodontitis as well as 
localized aggressive periodontitis. Figure 1 shows the distribution of sites among all groups. 
45.65% of the subjects were male and 54.35% were female with a mean age of 53.23 and a 
standard deviation of 4.33. The distribution of age and gender among groups can be found in 
Table 1. Additionally, table 1 shows the probing pocket depth (PPD) measurements in all groups 
at time of initial examination. Table 2 shows the levels of the analytes which were detected in 
this study. These include MFG-E8, OPG, RANKL, IL-1α, IL-1β, IL-6 and IL-17A. Table 3. 
shows the reduction in (PPD) in the treated severe periodontitis subgroup while Table 4 includes 
the cytokine levels of the analyses were detected in the treated severe periodontitis subgroup 
(MFG-E8, RANKL, IL-6 and IL-17A).  
Figure 2 shows the levels of detected analytes in all subject groups as well as differences 
in PPD. No significant difference was found in the levels of MFG-E8 in gingivitis and in health 
(p > 0.9999) but the levels in both groups were significantly higher than all periodontitis groups 
(p < 0.0001). The moderate periodontitis group showed significantly higher levels of MFG-E8 
than both the severe periodontitis group and the aggressive periodontitis group (p < 0.0005) but 
no significant difference was found between levels in severe periodontitis and sites with 
localized aggressive periodontitis (p > 0.9999). Figure 3 shows the scatter plot of the correlation 
between PPD and MFG-E8 in all sites at initial examination. Spearman’s rank correlation 
showed significant negative correlation between PPD and GCF MFG-E8 levels (r = -0.7101, p < 
0.0001). 
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When MFG-E8 was examined after non-surgical and surgical therapy in the severe 
periodontitis group, it was found that the level of MFG-E8 in GCF increases with decreasing 
probing pocket depths. The level of MFG-E8 was significantly higher after non-surgical therapy 
and further increased significantly after surgical therapy as periodontal pockets were eliminated 
(p < 0.0001) as seen in Figure 4. 
The level of OPG was found to follow a trend similar to MFG-E8 levels. It was found to 
be significantly higher in health and gingivitis as compared to periodontitis groups (p < 0.05). 
Moderate periodontitis had significantly higher levels of OPG when compared to severe (P = 
0.0026) and aggressive periodontitis (p < 0.0001). No significant differences were found 
between OPG levels in severe and aggressive periodontitis (p = 0.5604). RANKL, on the other 
hand, showed an opposing trend with significantly higher levels in the periodontitis groups as 
compared to health and gingivitis (P < 0.0001). No significant differences were found between 
the health and gingivitis group (p > 0.9999) or between all three periodontitis groups (p > 
0.9999). The level of RANKL was found to be reduced as probing depths were reduced. It was 
found to significantly reduce following non-surgical and surgical therapy (p < 0.0001). 
The level of IL-1α was also found to be significantly reduced in health and gingivitis as 
compared with periodontitis groups (p < 0.0450) with no significant differences among all three 
periodontitis groups and no significant difference between health and gingivitis (p > 0.9999). IL-
1β was significantly lower in health and gingivitis groups as compared to the periodontitis 
groups (p < 0.0001). No significant difference was found between health and gingivitis group (p 
> 0.9999) or among the periodontitis groups (p < 0.167). 
IL-6 was barely detectable in health and gingivitis groups with no significant differences 
between both groups but was significantly increased in periodontitis groups (p < 0.0001). The 
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moderate periodontitis group had significantly lower levels of IL-6 as compared to the severe 
periodontitis group (p = 0.0007) and the localized aggressive periodontitis group (p < 0.0001). 
No significant difference was found between the severe and localized aggressive periodontitis 
groups (p = 0.8767). IL-6 was also significantly reduced after surgical and non-surgical therapy 
(p < 0.0001). 
IL-17A was not detected in health and gingivitis but it was detected in all periodontitis 
groups with the highest level found in the localized aggressive periodontitis group. The level of 
IL-17A in the aggressive periodontitis groups was significantly higher than all other test groups 
(p < 0.0001 for healthy, gingivitis and moderate periodontitis. P = 0.0194 for severe 
periodontitis). Its level in the severe periodontitis group was significantly higher than the 
moderate periodontitis group (p = 0.0003) and both the health and gingivitis groups (p < 0.0001). 
Furthermore, the level of IL-17A in the moderate periodontitis group was significantly higher 
than the level in health and gingivitis (p < 0.0001). IL-17A was found to be significantly reduced 
following non-surgical and surgical therapy (p < 0.0001). 
 
 
DISCUSSION 
The results of the current study have shown that the secreted glycoprotein MFG-E8 can 
be detected in human gingival crevicular fluid in different states of health and disease using 
magnetic bead-based multiplexing assays. It was also found that the levels of MFG-E8 in human 
GCF were higher in cases of health and gingivitis than in periodontal disease, where they are 
inversely related to the severity of the disease. It was also shown to be decreased in areas 
affected with localized aggressive periodontitis. 
MFG-E8 and Periodontal Disease 28 
In sites with severe periodontitis that were examined after non-surgical and surgical 
periodontal treatment, it was found that total levels of MFG-E8 have increased at the re-
evaluation visit following non-surgical therapy as compared to the initial values. The levels of 
MFG-E8 further increased after surgical therapy which was inversely related to the decrease in 
probing pocket depth. 
These findings show that the levels of MFG-E8 decrease with increasing inflammation 
which is consistent with the findings of several authors in different inflammatory conditions such 
as sepsis [98-100], Alzheimer's disease [75, 76], atherosclerosis [74] and others [70]. MFG-E8 is 
produced by different cell-types in various tissues including epithelial cells, monocytes, 
macrophages, dendritic cells, fibroblasts, osteoblast, and osteoclasts. In general, the expression 
of MFG-E8 decreases under inflammatory conditions [70] In this regard, in sepsis, LPS inhibits 
the expression of MFG-E8 by macrophages [99]. Similarly, microbial LPS translocated into the 
periodontal lesions may inhibit the production of MFG-E8 by macrophages or other cell types 
that are commonly seen in the gingival corium subjacent to the epithelium that lines the gingival 
crevice. This would result in less MFG-E8 to reach the GCF via the gingival plexus of blood 
vessels in the gingival corium, a notion that is consistent with the data of this study. On the other 
hand, inflammation-induced osteoclastogenesis is accompanied by increased MFG-E8 
expression in the generated osteoclasts [95]. However, since the net effect of inflammation on 
MFG-E8 is a decrease of its levels in the GCF, it is possible that the osteoclast-derived MFG-E8 
represents a small fraction of its overall production in the periodontium or it is primarily 
consumed locally by the osteoclasts in an autocrine manner, as recently shown [95]. Another 
possibility might be that the osteoclast-derived proteins may not reach the GCF as readily as 
proteins by other cell types that are closer to the gingival crevice or periodontal pockets (for 
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instance, passive diffusion of proteins into the crevice should be facilitated by the proximity of 
their cellular source). In summary, periodontitis results in decreased levels of MFG-E8 in the 
GCF, whereas successful periodontal treatment or periodontal health are associated with 
relatively higher GCF levels of MFG-E8. The data of this study therefore suggest that MFG-E8 
can be considered as a novel biomarker for periodontal disease. 
Receptor activator of nuclear factor-κB ligand (RANKL) which is expressed by 
osteoblasts and other stromal cells plays a role in osteoclast differentiation thus leading to 
increased bone resorption [101]. Osteoprotegerin (OPG) blocks the activation of osteoclasts by 
preventing the activation of RANK on osteoclast progenitor cells by RANKL leading to 
decreased bone resorption. The interplay of OPG and RANKL plays a role in regulating 
periodontal bone loss [102].The RANKL and OPG findings of the current study are consistent 
with what was shown in previous studies in that the level on RANKL is up regulated in human 
GCF from periodontitis sites while OPG was down regulated [32-34, 37, 42]. Moreover, the 
level of RANKL in the current study was found to be reduced at re-evaluation as compared to 
initial values and was further reduced after surgical therapy.  
Overall, the investigation of different cytokines which play a role in periodontal disease, 
showed that the levels of pro-inflammatory and pro-osteoclastogenic cytokines IL-1α, IL-1β, IL-
17A, RANKL were up regulated with increasing periodontal disease severity while the levels of 
homeostatic molecules, OPG and MFG-E8, were down regulated.  
Levels of IL-1 were found to be lower in cases of health and gingivitis and were 
increased in moderate periodontitis, severe periodontitis and localized aggressive periodontitis. 
That is in agreement with the findings of pervious authors [25-27, 30, 37, 38, 40, 43, 45]. On the 
MFG-E8 and Periodontal Disease 30 
other hand, another study found a significantly higher levels of IL-1β in healthy sites when 
compared to disease sites using a multiplex bead-based assay [44]. 
IL-6 is a pro-inflammatory cytokine that is release by osteoblastic cells and interacts with 
other factors to induce bone resorption [11, 103, 104]. The human GCF levels of IL-6 in the 
current study were almost undetected in healthy and gingivitis sites while their levels were 
significantly increased in moderate and severe chronic periodontitis as well as in localized 
aggressive periodontitis. 
Following surgical and non-surgical treatment, it was found that the levels of IL-6 were 
reduced. This was also noted by Thunell [43] and Reis [105] where multiplex assays showed a 
significant reduction in IL-6 GCF levels in diseased sites after non-surgical therapy. Emingil also 
showed similar findings following treatment with Subantimicrobial-dose doxycycline. They 
found significant reduction in IL-6 levels up to nine months in sites with probing depths >7 mm 
[106]. These findings are inconsistent with the findings of de Lima Oliveira in generalized 
aggressive periodontitis cases [46].  
IL-17 is a pro-inflammatory cytokine that plays a role in many systemic inflammatory 
diseases such as rheumatoid arthritis, asthma and allergic diseases [107]. It exacerbates 
periodontal disease by increasing the production of inflammatory mediators from the gingival 
fibroblasts [108]. Moreover, IL-17 induces the expression of RANKL by osteoblasts [109]. The 
level of IL-17 in the current study was not detected in health and gingivitis sites. It was however 
detected in both chronic and aggressive periodontitis sites, consistent with the findings of Vernal 
et al [36]. 
IL-17 was reduced following non-surgical and surgical treatment. Similarly, the study by 
Emingil showed significantly lower levels of IL-17 following treatment with scaling and root 
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planing with subantimicrobial-dose doxycycline when compared to scaling and root planing 
alone. 
Although MFG-E8 is an anti-inflammatory protein [70] it is uncertain whether the down 
regulation of MFG-E8 contributes to periodontal tissue destruction as a result of defective 
regulation of the inflammation. Alternatively, or additionally, the inhibition of MFG-E8 
production in periodontitis may result in less efficient phagocytic uptake of apoptotic cells, 
thereby contributing to necrosis and enhanced local inflammation. Moreover, Abe et al showed 
that MFG-E8 knockout mice had increased osteoclastogenesis leading to increased periodontal 
bone loss [95]. Although osteoclasts produce MFG-E8, apparently the level of production is not 
sufficient to effectively restrain osteoclastogenesis and pathologic bone resorption in 
periodontitis. Therefore, local administration of MFG-E8 may be protective in periodontitis as 
suggested by an intervention study in mice, where local microinjection of MFG-E8 protected 
mice against periodontal bone loss. Further research is required to confirm if MFG-E8 has 
similar protective effects in higher animal species and in humans. This may potentially open the 
door for the use of MFG-E8 as a local adjunctive therapy against inflammatory periodontal bone 
loss. 
In the current study, multiple mediators were detected by analyzing the diluted fluid from 
a single paper strip by using 3 different kits. The use of multiplex bead-based immunoassays 
enabled the detection of multiple mediators from a single GCF strip. This offers a large 
advantage over the use of traditional methods such as ELISA.  
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CONCLUSIONS 
The results of the current study have shown for the first time the presence of MFG-E8 in 
human GCF collected from healthy, gingivitis and periodontitis subjects by using a magnetic 
bead-based immunoassay. 
The levels of MFG-E8 were negatively related to the level of gingival inflammation and 
were found to increase after surgical and non-surgical treatment of periodontal disease. This may 
indicate its value as a potential biomarker for periodontal inflammation. This may pave the way 
for future research in this field and the potential for development of therapeutic agents. 
Multiplexing bead-based immunoassays are capable of detecting multiple analytes in a 
single assay leading to findings that are consistent with other studies. 
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FIGURES 
 
 
Figure 1: Flowchart showing distribution of subjects and sites in each group. GCF 
testing was done at baseline for all groups. Repeated testing was done after non-surgical 
treatment and surgical treatment for a subgroup (30 sites) from the Chronic Severe Periodontitis 
group. 
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 Figure 2: Levels of different analytes and probing pocket depths (PPD) among groups. (A) 
MFG-E8, (B) IL-17A, (C) IL-6, (D) RANKL, (E) OPG, (F) IL-1, (G) IL-1 (H) PPD. Pm: 
Moderate Periodontitis, Ps: Severe Periodontitis, LAP: Localized Aggressive Periodontitis, G: 
Gingivitis, H: Healthy. * p < 0.05, ** p < 0.0005. 
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 Figure 3: Scatter plot of correlation between PPD and MFG-E8 in all subjects at initial 
examination. Significant negative correlation found between PPD and MFG-E8 (r-coefficient = -
0.7101, p-value < 0.0001).  
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 Figure 4: Change of levels of different analytes and probing pocket depths (PPD) in the 
treated severe periodontitis subgroup at initial examination, re-assessment and post-operation. 
(A) PPD, (B) MFG-E8, (C) IL-17A, (D) IL-6, (E) RANKL. * p < 0.05, ** p < 0.0005.   
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TABLES 
 Moderate 
Periodontitis 
Severe 
Periodontitis 
Aggressive 
Periodontitis 
Gingivitis Healthy 
 Mean SD Mean SD Mean SD Mean SD Mean SD 
PPD 4.13 1.24 5.60 1.55 6.70 1.58 2.57 0.78 2.09 0.56 
Age 53.32 6.28 52.35 5.66 19.32 3.33 56.78 4.23 49.88 6.57 
Gender 
(%) 
Male Female Male Female Male Female Male Female Male Female 
58.3% 41.7% 42.9% 57.1% 33.3% 66.7% 57.1% 42.9% 28.6% 71.4% 
 Table 1: Mean probing pocket depth (PPD), age and gender distribution among groups at 
time of initial GCF collection. 
 
 
 Moderate 
Periodontitis 
Severe 
Periodontitis 
Aggressive 
Periodontitis 
Gingivitis Healthy 
 Mean SD Mean SD Mean SD Mean SD Mean SD 
MFG-E8 27.00 5.26 12.38 5.88 10.60 5.32 43.82 5.67 41.76 6.77 
OPG 120.93 37.50 93.69 29.72 75.65 36.69 175.68 53.84 162.10 55.36 
RANKL 134.95 23.09 143.73 35.58 140.07 32.68 48.32 20.94 37.60 13.06 
IL-1α 476.01 324.55 525.16 342.00 503.67 266.34 275.45 188.81 191.13 142.58 
IL-1β  531.31 134.73 597.81 133.52 651.68 179.22 189.11 68.43 132.43 63.31 
IL-6 587.36 150.24 754.01 146.52 865.53 170.66 102.74 36.44 45.45 18.07 
IL-17A 15.93 6.22 24.11 4.85 34.20 6.22 0.03 0.03 0.03 0.03 
 Table 2: Mean level of MFG-E8, OPG, RANKL, IL-1α, IL-1β, IL-6 and IL-17A among 
groups at time of initial GCF collection. 
 
Treatment 
Subgroup 
Initial Reevaluation Post Surgery 
 Mean SD Mean SD Mean SD 
PPD 6.03 1.61 3.97 1.07 2.63 0.67 
 Table 3: Mean probing pocket depth (PPD) in severe periodontitis treatment subgroup at 
time of initial GCF collection, 4-week re-evaluation appointment after non-surgical therapy and 
4-week postoperative appointment after pocket reduction surgery. 
 
Treatment 
Subgroup 
Initial Reevaluation Post Surgery 
 Mean SD Mean SD Mean SD 
MFG-E8 11.31 3.42 17.03 5.47 27.78 7.51 
RANKL 149.29 30.27 107.92 23.61 67.67 16.41 
IL-6 799.76 138.28 323.20 178.82 152.70 69.42 
IL-17A 25.64 5.15 21.64 5.55 12.16 4.93 
 Table 4: Mean levels of MFG-E8, RANKL, IL-6, IL-17A in severe periodontitis treatment 
subgroup at time of initial GCF collection, 4-week re-evaluation appointment after non-surgical 
therapy and 4-week postoperative appointment after pocket reduction surgery. 
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